Navigation Links
Trius Reports New Findings on Mechanisms of Antibiotic Resistance in MRSA
Date:9/13/2010

m Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the potential benefits of torezolid phosphate. Risks that contribute to the uncertain nature of the forward-looking statements include: Trius' ability to obtain additional financing; the success and timing of Trius' preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; the performance of third-party manufacturers; changes in Trius' plans to develop and commercialize its product candidates; Trius' ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Trius' most recently filed SEC documents, including its Registration Statement on Form S-1 that was originally filed with the United States Securities and Exchange Commission on November 6, 2009, and the amendments thereto, and Trius' Form 10-Q for the quarter ended June 30, 2010, including those factors discussed under the caption "Risk Factors" in such filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trius undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trius to Present at the Stifel Nicolaus Healthcare Conference
2. Trius Therapeutics Obtains Special Protocol Assessment With FDA for Phase 3 Study of Torezolid Phosphate
3. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
4. Trius Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting
5. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
6. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
7. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
8. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
9. Trius Doses First Patient in Antibacterial Phase 2 Trial
10. PacificGMP Completes GMP Product Fill for Trius Therapeutics
11. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kz78wm/medical_device ) ... Device Studies: Clinical Evidence" conference to their ... specifically for those who are involved in gathering ... diagnostic products. Clinical data is required for all ... appropriate clinical evidence has grown substantially in the ...
(Date:4/1/2015)... Md. , April 1, 2015  RegeneRx ... today announced that a new medical paper has ... beta 4 (TB4) in patients with severe dry ... the study and the physicians stated that statistically ... severe dry eye were seen at various time ...
(Date:4/1/2015)... LAVAL, Quebec , April 1, ... Inc. (NYSE: VRX and ... completed the previously announced acquisition of ... a specialty pharmaceutical company that offers ...  (rifaximin) 550 mg, RUCONEST ®  (C1 esterase inhibitor ...
Breaking Medicine Technology:Medical Device Studies: Clinical Evidence Seminar - London, UK, 13th, 14th of May 2015 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 3
... Md., June 7, 2011 EntreMed, Inc. (Nasdaq: ... for the treatment of cancer, today announced that Selected ... to acquire an exclusive license to develop and commercialize ... and certain of its territories.  EntreMed retains development and ...
... pleased to announce the availability of custom radiolabeling services for ... July 2011. This is part of the company,s ongoing initiative ... the biopharma and research community and is synergistic with existing ... past 18 months we have grown our core antibody engineering ...
Cached Medicine Technology:Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China 2Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China 3Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China 4ImaginAb, Inc. Announces Availability of Custom Protein Radiolabeling Services for Molecular Imaging 2
(Date:4/1/2015)... Peoria, Ill. (PRWEB) April 01, 2015 ... the OSF Healthcare System , was welcomed into ... Dedication Ceremony officiated by Msgr. Paul E. Showalter, vicar ... , The Blessing and Dedication culminated a nearly year-long ... the eleventh OSF HealthCare hospital. Speakers for the morning ...
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 ... senior care, today announces the launch of the ... innovative senior care stakeholders and technology companies. The announcement ... Center (NIC) Capital and Business Strategies Forum in ... members, the new Alliance program is now open for ...
(Date:4/1/2015)... Dr. Rod J. Rohrich , Dallas ... Department of Plastic Surgery at UT Southwestern Medical Center, ... blindness resulting from the use of facial aesthetic ... study, along with ideas for treatment and prevention in ... to see increasing reports of blindness as a result ...
(Date:4/1/2015)... GA (PRWEB) April 01, 2015 ... Medicine Practice, Pediatric Emergency Medicine Practice, and Hospital ... has partnered with AgileMD to provide the content ... , in a mobile application format available on ... , “Our collaboration with AgileMD to develop mobile ...
(Date:4/1/2015)... 2015 Skin cancer is one of the ... caught early. Forefront Dermatology and Dermatology Associates of Wisconsin want ... before it spreads so they are hosting a free skin ... 8:30am - 12:30pm. , “If we can see the ... concern, that could become cancerous,” said Dr. Ken Katz, who ...
Breaking Medicine News(10 mins):Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 3Health News:Forefront Dermatology and Dermatology Associates of Wisconsin Offers Skin Cancer Screenings on April 11th 2
... for patients with the Anakam Identity Suite(R) , ... that Sharp HealthCare, San Diego County,s largest healthcare system, ... access for patients accessing Sharp,s new patient portal. ... meet the needs of its patient community by providing ...
... , FORT LAUDERDALE, Fla., June 24 Argentech, Inc. ... reached agreement with Invision International Health Solutions, Inc., to ... antiviral technology that utilizes ionic silver in a unique ... complex was granted broad patent protection in the U.S. ...
... Cancer Institute scientists, discovery of a cancer-causing gene the ... demonstrates how the panoramic view of genomics and the close-up ... are involved in cancer and which are mere bystanders. The ... journal Nature . "In the coming years, we ...
... Minn., June 24 The Mayo Clinic Center for ... on innovations in health care experience and delivery, Sept. ... the public. It will feature nationally recognized speakers on ... care delivery models, including Web-based tools. The center,s work ...
... study finds , WEDNESDAY, June 24 (HealthDay News) -- ... taking drugs to prevent osteoporosis is unnecessary and could ... Australian researchers analyzed data from a large randomized trial ... widely used bisphosphonate) in more than 6,000 postmenopausal women ...
... 24, 2009 Furthering its mission to improve ... (USP) Convention has signed a cooperative agreement with ... Asian Nations (ASEAN). In a drive to strengthen ... control laboratories, officials from Cambodia, Laos, Myanmar, Singapore, ...
Cached Medicine News:Health News:Sharp HealthCare and Anakam(R) Partner to Protect Patients' Health Information 2Health News:Sharp HealthCare and Anakam(R) Partner to Protect Patients' Health Information 3Health News:Potential Silver Bullet for Swine Flu and Most Common Infections Using Green Technology Patented in U.S. and Mexico 2Health News:Potential Silver Bullet for Swine Flu and Most Common Infections Using Green Technology Patented in U.S. and Mexico 3Health News:Study pinpoints novel cancer gene and biomarker 2Health News:Study pinpoints novel cancer gene and biomarker 3Health News:Study pinpoints novel cancer gene and biomarker 4Health News:Mayo Clinic Center for Innovation to Sponsor a Collaborative Symposium on Innovations in Health Care Experience and Delivery 2Health News:Mayo Clinic Center for Innovation to Sponsor a Collaborative Symposium on Innovations in Health Care Experience and Delivery 3Health News:Bone Therapy May Not Always Need Monitoring 2Health News:Goal of good quality medicines advanced by new USP agreement with 9 ASEAN countries 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: